



**Editor-in-Chief**  
Pedro T Ramirez (USA)

**Associate Editors**  
Giovanni Damiano Aletti (Italy)  
Michael Frumovitz (USA)  
Anuja Jhingran (USA)  
Ainhoa Madariaga (Spain)  
Rene Pareja (Colombia)

**Video Editors**  
Luis Chiva (Spain)  
Houssein El Hajj (France)

**Social Media Editors**  
Andreina Fernandes (Venezuela)  
Aarthi S. Jayraj (United Kingdom)

**Managing Editor**  
Emily Hammond (USA)

**Editorial Office**  
*International Journal of Gynecological Cancer*, BMJ Journals  
Two Hudson Square, 3rd Floor,  
Hoboken, NJ 07030 USA  
E: [ijgc@ijeditorial.com](mailto:ijgc@ijeditorial.com)

**Production Editor**  
Hannah Martin  
E: [production.ijgc@bmj.com](mailto:production.ijgc@bmj.com)

**Customer support**  
For general queries and support with  
existing and new subscriptions:  
W: [support.bmj.com](mailto:support.bmj.com)  
T: +44 (0)20 7111 1105  
E: [support@bmj.com](mailto:support@bmj.com)

Self-archiving and permissions  
W: [www.bmj.com/company/products-services/rights-and-licensing/](http://www.bmj.com/company/products-services/rights-and-licensing/)  
E: [bmj.permissions@bmj.com](mailto:bmj.permissions@bmj.com)

**Disclaimer:** The Editor of *International Journal of Gynecological Cancer* has been granted editorial freedom and *International Journal of Gynecological Cancer* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *International Journal of Gynecological Cancer* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *International Journal of Gynecological Cancer* does not imply endorsement. Neither *International Gynecologic Cancer Society* and *European Society of Gynaecological Oncology* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *International Journal of Gynecological Cancer* (except for liability which cannot be legally excluded).

**Copyright:** © 2024 IGCS and ESGO. All rights reserved; no part of this publication may be reproduced in any form without permission.

*The International Journal of Gynecological Cancer (IJGC)* is published by BMJ Publishing Group Ltd and typeset by Exeter Premedia Services Private Limited, Chennai, India.

## Lead Article

- 1661** Racial and sociodemographic disparities in the use of targeted therapies in advanced ovarian cancer patients with Medicare  
*A Knisely, C-F Wu, A Kanbergs, N Agusti, K A Jorgensen, A Melamed, S H Giordano, J A Rauh-Hain, R Nitecki Wilke*

## Editorial

- 1671** Bridging the gap: ensuring equitable access to advancements in gynecologic cancer therapies  
*J M Patel, E Aviki*

## Consensus statement

- 1673** ESGE/ESGO/SERGS consensus statement on surgical steps in minimally invasive surgery in gynecologic oncology: transperitoneal and extraperitoneal approach for paraaortic lymphadenectomy  
*R Rovira, L Mereu, F Planchamp, H Falconer, A El-Balat, M Barahona, A Fagotti, D Querleu, C Taskiran*

## Society statements

- 1677** How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting  
*J Sehouli, J Boer, A H Brand, A M Oza, J O'Donnell, K Bennett, R Glaspool, C K Lee, J-L Ethier, P Harter, V Seebacher-Shariat, T-C Chang, P A Cohen, T van Gorp, A Chavez-Blanco, S Welch, H Hranovska, S O'Toole, C A R Lok, A Madariaga, J A Rauh-Hain, A Perez Fidalgo, D Tan, J Michels, B Pothuri, N Fujiwara, O Rosengarten, H Nishio, S I Kim, A Mukopadhyay, E Piovano, S C Cecere, E C Kohn, U Mukherjee, S Nasser, K Lindemann, J Croke, X Chen, F Geissler, M A Bookman*
- 1685** Gender equality, diversity, and inclusion among gynaecologic oncologists: European Network of Young Gynae Oncologists (ENYGO)–European Society of Gynaecological Oncology (ESGO) project  
*T Nikolova, E Bilir, N Bizzarri, C Fotopoulou, T van Gorp, J Kacperczyk-Bartnik, Z Razumova, A N Strojna, A G Eriksson, M Pakiz, M R Mirza, A Fagotti, N Concin*

## Cervical Cancer

- 1691** Comparing visual inspection with acetic acid, with and without Lugol's Iodine for triage of HPV self-sample positive women in Ethiopia: a randomized controlled trial  
*S F Mekuria, H Biazin, T Abebe, C Borgfeldt, N Assegid, A Mihret, R Obsi Nemomsa, O Forslund, M Jerkeman*
- 1698** Scaling cervical cancer screening in Mozambique: analysis of loop electrosurgical excision procedure (LEEP) specimens  
*S Chambule, R Rangeiro, S Batman, E Lathrop, N Osman, A Neves, A A N Mariano, J C Nkundabatware, C Carrilho, E C S Monteiro, R Paulo Mugolo, J P Thomas, J Carns, V Andrade, H Atif, E Baker, B M Fellman, R Richards-Kortum, K M Schmeler, C Lorenzoni, M P Salcedo*
- 1704** Association between Silva pattern-based classification and endocervical adenocarcinoma: a systematic review and meta-analysis  
*M Chen, L Han, Y Wang, Y Chen, A Zheng*

## Uterine Cancer

- 1711** Tumoral programmed cell death 1 (PD1) expression in endometrial carcinoma is a prognostic marker for patient outcome  
*B Feroz, T L Pan, K Leitner, C Ebner, K Steger, W Kildal, G Kristensen, A G Zeimet, H Hackl, H Fiegl, C Marth, V Wieser*
- 1719** Real-world use of immune checkpoint inhibitors in advanced or recurrent endometrial cancer  
*S Huepenbecker, L A Meyer, M Craft, J K Chan, C Craggs, P Lambert, Y G Lin*
- 1729** Lymph node dissection after neoadjuvant chemotherapy improves overall survival in clinical stage III endometrial cancer  
*M E Lander, J A Vargo, R Buckanovich, A Garrett, P Barry, P Sukumvanich*
- 1737** Association of glutaminase expression with immune-suppressive tumor microenvironment, clinicopathologic features, and clinical outcomes in endometrial cancer  
*S Asaka, N Verma, T-T Yen, J L Hicks, H Nonogaki, Y-A Shen, J Hong, R Asaka, A M DeMarzo, T-L Wang, I-M Shih, S Gaillard*

## Ovarian Cancer

- 1745** Predicting outcomes in malignant ovarian germ cell tumors using the modified International Germ Cell Cancer Collaborative Group classification system  
*X Zhang, J Yang, Y Xiang, M Wu, D Cao, J Wang, J Yang*
- 1753** Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe  
*K N Moore, M R Mirza, C Gourley, S Pignata, D Lorusso, B J Monk, J Sehoul, J M Schilder, N D'Esquermes, A González-Martín*
- 1761** Efficacy and safety of an oral combination therapy of niraparib and etoposide in platinum resistant/refractory ovarian cancer: a single arm, prospective, phase II study  
*H Zhou, Q Liu, D Zhang, Q Li, D Cao, N Cheng, X Wan, Y Zhang, F Feng, Y Xiang, J Yang*
- 1768** Venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer  
*S Oxley, S Ahmed, K Baxter, D Blake, V Braden, M R Brincat, S Bryan, J Dilley, S Dobbs, A Durden, N Gomes, B Johnston, S Kaushik, F Kokka, M Lockley, J Lowe-Zinola, R Manchanda, A McCormick, C Nott, G L Owens, A Pandya, J Prince, N Ryan, N Ryan, M Sideris, S Tanna, J Waters, N Zamesa, M Thomas, A Olaitan*
- 1775** Anastomotic diversion rates following integration of indocyanine green fluorescence angiography in cytoreductive surgery for ovarian cancer  
*L Salman, L Hogen, M Maganti, T May*
- 1780** Changes in the tumor immune microenvironment during disease progression in clear cell ovarian cancer  
*H Y Woo, N Y Kim, J Jun, J-Y Lee, E J Nam, S W Kim, S-H Kim, Y-T Kim, Y J Lee*
- 1787** Key issues in diagnostic accuracy of sentinel lymph node biopsy in early-stage ovarian cancer: systematic review and meta-analysis  
*I Rey, V Lago, M Arnáez, N Bizzarri, N Agustí, C Nero, B Díaz-Feijoo, P Padilla-Iserte, S Domingo*

## Reviews

- 1795** The clinical landscape of antibody-drug conjugates in endometrial cancer  
*G Fucà, I Sabatucci, M Paderno, D Lorusso*

- 1805** Assessing minimally invasive simple hysterectomy in low risk cervical cancer: set up for the LASH trial  
*N Bizzarri, N R Abu-Rustum, M Plante, P T Ramirez, L Chiva, H Falconer, D Cibula, D Querleu, F Fanfani, A Fagotti, G Scambia*

## Clinical trial

- 1809** A randomized phase II study of secondary cytoreductive surgery in patients with relapsed ovarian cancer who have progressed on a PARP inhibitor as first-line maintenance therapy: the SOCCER-P study (KGOG 3067/JGOG 3036/APGOT-OV11)  
*H-W Cho, H-S Kim, J-Y Park, Y Y Lee, M C Lim, S-J Lee, K-J Min, K J Eoh, K B Lee, M K Kim, J Y Song, S-H Shim, Y I Ji, Y-J Song, S-J Chang, M K Kim, A Abe, Y Kobayashi, H Kajiyama, M Shimada, A Okamoto, J S Ng, J-Y Lee*

## Tumor board

- 1813** Non-invasive mediastinal lymph node metastasis of serous borderline ovarian tumor  
*M M Canturk, B Giray, D Vatanserver, E E Donmez, O Turkkkan, F N Kapucuoglu, D Tunali, C Taskiran*

## Corners of the world

- 1820** Intercultural dialogues and multilevel strategies for cervical cancer prevention for the Arhuacos indigenous community in Colombia  
*A R Zambrano Harvey, L M Galvis-Cataño, F J Bonilla-Escobar, M A Zapata Izquierdo*

## Video articles

- 1822** Diaphragmatic and pericardiac ovarian cancer recurrence removal and mesh reconstruction  
*A Rychlik, M Bedyńska, P Hevelke*

- 1824** Vulvar cancer resection with V-Y advancement flap reconstruction  
*K L Morales Palomino, S Domingo Del Pozo, M Gurrea, M Arnaez, V Lago, P Padilla-Iserte*

- 1826** Total pelvic exenteration with radical vulvectomy and anorectal resection in 10 steps

*E Gauroy, J Suhner, T Meresse, G Ferron, E Chantalat, A Martinez*

---

## Pathology archives

- 1828** Mixed neuroendocrine and endometrioid carcinoma of the endometrium: a rare aggressive malignancy

*N Bakshi, R D Modi, M Srivastava, S Badwal*

---

## Images

- 1831** Mapping the path: round ligament metastasis in ovarian cancer

*A S Jayraj, S Singhal*

---

## Commentaries

- 1833** FDA approves the first HPV self-collection solutions

*E Bilir, K G Saçntı, J Kacperczyk-Bartnik, M Gultekin*

- 1834** Role of secondary cytoreduction in relapsed ovarian cancer

*M C Gouveia, Y R Shinkado, A J Rossi, G Baiocchi, M Scaranti*

---

## Research communication

- 1836** Dynamic changes in *TP53* mutated circulating tumor DNA predicts outcome of patients with high-grade ovarian carcinomas

*M Kfoury, C Bonnet, N Delanoy, K Howarth, C Marzac, E Rouleau, J-B Micol, A Leary*

---

## Letters

- 1840** Correspondence on 'An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial)' by Chiva et al

*M Signorelli, R Fossati*

- 1841** Response to: Correspondence on 'An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial)' by Chiva et al.

*L Chiva, P Ordás*